@misc{2517a5b375cc4fb4845b576ae597911b,
title = "Antibodies specifically directed to a soluble form of CTLA-4",
abstract = "The invention provides materials and methods relating to antibodies specific for a soluble form of CTLA-4 (sCLTA-4). Such antibodies have been shown to have a strong boosting effect on antigen-specific human immune responses.",
author = "Ward, {Frank James} and Barker, {Robert Norman} and Dahal, {Lekh Nath}",
note = "New antibody molecule that binds specifically to soluble form of cytotoxic T-lymphocyte antigen, useful as vaccine e.g. to enhance antigen specific immune response against pathogens e.g. bacteria, virus e.g. HIV, and nematode Patent Number(s): WO2010097597-A1 Original ; AU2010217453-A1 ; EP2401035-A1 Original ; CN102421482-A ; US2012107320-A1 Original ; CA2772648-A1 ; JP2012518425-W ; IN201106831-P4 ; US8697845-B2 Original ; JP5864266-B2 ; CN102421482-B ; AU2010217453-B2 ; EP2401035-B1 Original ; ES2662652-T3; US8697845 B2",
year = "2010",
month = sep,
day = "2",
language = "English",
type = "Patent",
}